Onglyza (Saxagliptin)

Saxagliptin, the active ingredient in Onglyza, is a dipeptidyl peptidase-4 (DPP‑4) inhibitor presented as a tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus. GNH USA supplies Onglyza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Onglyza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Saxagliptin is a DPP‑4 inhibitor that targets the incretin pathway to help manage blood glucose levels in type 2 diabetes. - Type 2 diabetes mellitus: improves fasting and post‑prandial glucose control when used with diet and exercise. - Combination therapy with metformin: provides additional glycaemic reduction for patients inadequately controlled on metformin alone. - Combination therapy with insulin: assists in lowering HbA1c alongside basal or prandial insulin regimens.